MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Stephanie B Syc-MazurekHannah Zhao-FlemingYong GuoNanthaya TisavipatJohn J ChenAnastasia ZekeridouIoannis KournoutasJacob J OrmeMatthew S BlockClaudia F LucchinettiRafid MustafaEoin Patrick FlanaganPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
This case revealed a presentation of MOGAD concurrent with melanoma without tumor MOG immunostaining. We highlight tocilizumab as a dual-purpose treatment of MOGAD and the neurologic immune-related adverse effect of ICI.